If you have been reading about peptide purity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-12. Numbers and descriptions here follow the published literature rather than marketing material.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
On 27 May 2021, Danish epidemiologist Tina Fischer spoke on the This Week in Virology podcast, advocating for a second phase of the study to audit blood samples for COVID-19 antibodies in China. WHO-convened study team member Marion Koopmans, on that same broadcast, advocated for WHO member states to make a decision on the second phase of the study, though she also cautioned that an investigatory audit of the laboratory itself may be inconclusive. In early July 2021, WHO emergency chief Michael Ryan said the final details of phase 2 were being worked out in negotiations between WHO and its member states, as the WHO works "by persuasion" and cannot compel any member state (including China) to cooperate. In July 2021 China rejected WHO requests for greater transparency, cooperation, and access to data as part of Phase 2. On 16 July 2021, Foreign Ministry spokesperson Zhao Lijian declared that China's position was that future investigations should be conducted elsewhere and should focus on cold chain transmission and the US military's labs. On 22 July 2021, the Chinese government held a press conference in which Zeng Yixin, Vice Health Minister of the National Health Commission (NHC), said that China would not participate in a second phase of the WHO's investigation, denouncing it as "shocking" and "arrogant". He elaborated "In some aspects, the WHO's plan for next phase of investigation of the coronavirus origin doesn't respect common sense, and it's against science.
The third zone is called the Steady-State Zone (SSZ), macropores in this region are aligned with one another and grow in a regular fashion. Within the SSZ, the structure is defined by a value λ that is the average thickness of a ceramic wall and its adjacent macropore.
=== Quartz fiber filter === Quartz fiber filter paper has a high resistance to chemicals, does not absorb NOx and SOx dioxides, is unaffected by humidity and is easily sterilized. Thus, it is mostly used for air pollution analysis.
=== Chemical synthesis === The chemical synthesis is similar to the biosynthesis, starting from the unsaturated compound without a cyclopropane ring, the vaccenic acid. In a Simmons-Smith reaction, a carbene is added to the double bond of the unsaturated fatty acid; diiodomethane and zinc are used to form the carbene. The Simmons-Smith reaction is stereospecific, for the preparation of cis-11,12-methylenoctadecenoic acid (lactobacillic acid) the cis-11-octadecenoic acid (cis-vaccenoic acid) is used. This can be of natural origin or synthesized from 11-octadecic acid.
Anti-Ro and anti-La antibodies, also known as SS-A and SS-B, respectively, are commonly found in primary Sjögren's syndrome, an autoimmune disorder that affects the exocrine glands. The presence of both antibodies is found in 30–60% of Sjögren's syndrome, anti-Ro antibodies alone are found in 50–70% of Sjögren's syndrome and 30% of SLE with cutaneous involvement, and anti-La antibodies are rarely found in isolation. Anti-La antibodies are also found in SLE; however, Sjögren's syndrome is normally also present. Anti-Ro antibodies are also found less frequently in other disorders including autoimmune liver diseases, coeliac disease, autoimmune rheumatic diseases, cardiac neonatal lupus erythematosus and polymyositis. During pregnancy, anti-Ro antibodies can cross the placenta and cause heart block and neonatal lupus in babies. In Sjögren's syndrome, anti-Ro and anti-La antibodies correlate with early onset, increased disease duration, parotid gland enlargement, disease outside the glands and infiltration of glands by lymphocytes. Anti-Ro antibodies are specific to components of the Ro-RNP complex, comprising 45kDa, 52kDa, 54kDa and 60kDa proteins and RNA. The 60kDa DNA/RNA binding protein and 52kDa T-cell regulatory protein are the best characterised antigens of anti-Ro antibodies. Collectively, these proteins are part of a ribonucleoprotein (RNP) complex that associate with the human Y RNAs, hY1-hY5. The La antigen is a 48kDa transcription termination factor of RNA polymerase III, which associates with the Ro-RNP complex.
Sources: en.wikipedia.org
== Image and legacy == Noriega's authoritarian rule of Panama has been described as a dictatorship, while Noriega himself has been referred to as a "strongman". A 2017 obituary from the BBC stated that Noriega "was an opportunist who used his close relationship with the United States to boost his own power in Panama and to cover up the illegal activities for which he was eventually convicted". A 2010 article in The Guardian referred to him as the best known dictator of his time, and as "Panama's answer to Libyan leader Colonel Muammar Gaddafi". Dinges writes that though Noriega's regime saw a number of murders and crimes, they were similar in scale to those that occurred at the same time under the authoritarian governments of Guatemala, Chile, Argentina, and El Salvador; these governments never saw the level of condemnation from the U.S. that Noriega's did. Others likened him to former Iraqi president Saddam Hussein. Like Saddam, Noriega enjoyed brief U.S. support until he turned into an enemy. After Noriega's death, an article in The Atlantic compared him to Castro and Augusto Pinochet, stating that while Castro had been the nemesis of the U.S., and Pinochet had been its ally, Noriega had managed to be both. It called Noriega the archetype of U.S. intervention in Latin America: "The lawless, vicious leader whom the U.S. cultivated and propped up despite clear and serious flaws." The author stated that although Panama was a freer democracy after Noriega's removal, it was still plagued by corruption and drug trafficking, while Daniel Ortega, whom the U.S.
== External links == Media related to Phyllostachys nigra at Wikimedia Commons Data related to Phyllostachys nigra at Wikispecies "Phyllostachys nigra". Integrated Taxonomic Information System. John Lindley (1835). "Description of Bambusa nigra". The Penny Cyclopædia of the Society for the Diffusion of Useful Knowledge. Vol. 3. p. 357.
denaturation The process by which nucleic acids or proteins lose their quaternary, tertiary, and/or secondary structures, either reversibly or irreversibly, through the application of some external chemical or mechanical stress, e.g. by heating, agitation, or exposure to a strong acid or base, all of which can disrupt intermolecular forces such as hydrogen bonding and thereby change or destroy chemical activity. Denatured proteins may be both a cause and a consequence of cell death. Denaturation may also be a normal process; the denaturation of double-stranded DNA molecules, for example, which breaks the hydrogen bonds between base pairs and causes the separation of the duplex molecule into two single strands, is a necessary step in DNA replication and transcription and hence is routinely performed by enzymes such as helicases. The same mechanism is also fundamental to laboratory methods such as PCR.
In glycolysis, glucose and glycerol are metabolized to pyruvate. Glycolysis generates two equivalents of ATP through substrate phosphorylation catalyzed by two enzymes, phosphoglycerate kinase (PGK) and pyruvate kinase. Two equivalents of nicotinamide adenine dinucleotide (NADH) are also produced, which can be oxidized via the electron transport chain and result in the generation of additional ATP by ATP synthase. The pyruvate generated as an end-product of glycolysis is a substrate for the citric acid cycle. Glycolysis is viewed as consisting of two phases with five steps each. In phase 1, "the preparatory phase", glucose is converted to 2 d-glyceraldehyde-3-phosphate (g3p). One ATP is invested in Step 1, and another ATP is invested in Step 3. Steps 1 and 3 of glycolysis are referred to as "Priming Steps". In Phase 2, two equivalents of g3p are converted to two pyruvates. In Step 7, two ATP are produced. Also, in Step 10, two further equivalents of ATP are produced. In Steps 7 and 10, ATP is generated from ADP. A net of two ATPs is formed in the glycolysis cycle. The glycolysis pathway is later associated with the Citric Acid Cycle, which produces additional equivalents of ATP. Glycolysis is regulated allosterically by a number of metabolic compounds. For example, hexokinase is directly inhibited by its product, glucose-6-phosphate, and pyruvate kinase is inhibited by ATP itself. The main control point for the glycolytic pathway is phosphofructokinase 1 (PFK1), which is allosterically inhibited by high concentrations of ATP and activated by high concentrations of AMP.
== Status == In the context of perpetual motion machines such as the Orbo, Professor Eric Ash has argued at the BBC: "Denying [conservation of energy] would undermine not just little bits of science - the whole edifice would be no more. All of the technology on which we built the modern world would lie in ruins". It is because of conservation of energy that "we know - without having to examine details of a particular device - that Orbo cannot work." Energy conservation has been a foundational physical principle for about two hundred years. From the point of view of modern general relativity, the lab environment can be well approximated by Minkowski spacetime, where energy is exactly conserved. The entire Earth can be well approximated by the Schwarzschild metric, where again energy is exactly conserved. Given all the experimental evidence, any new theory (such as quantum gravity), in order to be successful, will have to explain why energy has appeared to always be exactly conserved in terrestrial experiments. In some speculative theories, corrections to quantum mechanics are too small to be detected at anywhere near the current TeV level accessible through particle accelerators. Doubly special relativity models may argue for a breakdown in energy-momentum conservation for sufficiently energetic particles; such models are constrained by observations that cosmic rays appear to travel for billions of years without displaying anomalous non-conservation behavior.
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.